Predictors of Patient Adherence to Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder

Michael J. Maher a, Yuanjia Wang b, Allan Zuckoff b, Melanie M. Wall b, Martin Franklin b, Edna B. Foa a, Helen Blair Simpson d e

a Department of Clinical Therapeutics, New York State Psychiatric Institute, b Department of Biostatistics, Mailman School of Public Health, Columbia University, and c Department of Psychiatry, Columbia University, New York, N.Y.; d Departments of Psychology and Psychiatry, University of Pittsburgh, Pittsburgh, Pa.; e Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pa., USA

Cognitive-behavioral therapy consisting of exposure and response prevention (EX/RP) is an effective treatment for obsessive-compulsive disorder (OCD). However, only about half of patients achieve minimal or no symptoms by the end of treatment [1–3]. Identifying factors that lead to poor outcome and developing interventions to address them is one way to maximize the effects of EX/RP. Patient adherence to EX/RP is a strong predictor of EX/RP outcome [4, 5]. Specifically, during EX/RP treatment, therapists teach patients to face feared situations and thoughts (exposures) and to refrain from compulsive behaviors (response prevention). However, no prior study has systematically examined what predicts patient adherence to EX/RP procedures.

We examined potential predictors of patient adherence to EX/RP and whether patient adherence mediated the relationship between these predictors and post-treatment OCD severity. The sample consisted of 28 adults (18–70 years old) with OCD who received EX/RP as part of a clinical trial described in detail elsewhere [3]. In brief, patients participated in 8 weeks of EX/RP that included 3 introductory sessions and 15 twice-weekly 90-minute exposure sessions following the guidelines of Kozak and Foa. Patient adherence was measured at each exposure session using the Patient EX/RP Adherence Scale (PEAS) [7]; it assessed the quantity and quality of between-session exposures and the degree of response prevention practiced for homework. OCD symptoms were rated by independent evaluators using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [8, 9]. We examined four factors hypothesized to affect cognitive-behavioral therapy adherence in other patient groups [3, 10–12]: treatment expectancy using the Expectancy Questionnaire [10], therapeutic alliance using the Working Alliance Inventory – Self Report (WAI-SR) [12], readiness for change using the University of Rhode Island Change Assessment (URICA) [13], and readiness for treatment using the Readiness Ruler [3]. These measures were completed after the 3 introductory sessions and before exposure sessions began. We also examined baseline characteristics that predicted EX/RP outcome in prior OCD studies [14]. These included depressive severity as measured by the 17-item Hamilton Depression Rating Scale [15], insight on the Brown Assessment of Beliefs Scale [16], quality of life as measured by the Quality of Life and Enjoyment Questionnaire [17], Axis I comorbidity using the SCID-I [18], total number of serotonin reuptake inhibitor trials, female gender, employment status, work impairment as measured by an item on the Sheehan Disability Scale [19], and hoarding subtype.

Simple linear regression examined potential bivariate predictors of adherence. Significant predictors (p < 0.05) were then considered in subsequent mediation analyses (using Mplus 6.1) that involved simultaneous multiple regressions of adherence on all predictors and of treatment outcome (measured by post-treatment Y-BOCS adjusting for baseline Y-BOCS) on all predictors and adherence. Significant predictors (p < 0.05) of adherence and outcome in these multiple regressions were retained and their indirect effects (mediation effects) on treatment outcome through adherence were estimated and delta method standard errors were used for 95% confidence intervals and testing [20]. Data from all patients having a PEAS score were used (n = 28) and full information maximum likelihood was implemented in Mplus to account for missing post-treatment Y-BOCS scores (3 subjects dropped out from EX/RP treatment after session 9). Estimates were standardized to facilitate interpretation across predictors with different units.

The relationship between potential predictors and patient adherence to between-session EX/RP assignments based on simple regressions is presented in table 1. The 6 significant (p < 0.05) bivariate predictors of patient adherence were entered into mediation analyses and their estimated indirect effects are presented in table 1. Therapeutic alliance (WAI-SR, beta = 0.53), treatment readiness (Readiness Ruler, beta = 0.38), and hoarding status (beta = –0.26) all had significant (p < 0.05) independent effects on patient adherence. Patient adherence also had a significant direct effect (beta = –0.57, p < 0.01) on outcome and significantly mediated the impact of these other predictors on post-treatment OCD severity (table 1, indirect effects). The effects for treatment expectancy and readiness to change (URICA) were not significant in these mediation analyses. Work impairment (Sheehan Disability Scale) was not significantly associated with patient adherence, although it directly predicted post-treatment OCD severity (0.40, p < 0.01).

Our findings have several implications. First, therapeutic alliance (measured by the WAI-SR) predicted treatment outcome through its impact on patient adherence. The WAI-SR assessed patients’ attitudes about EX/RP strategies and goals presented by the therapist, and patients’ trust in the therapist. This suggests that taking time to understand patients’ symptoms and to care-
fully explain treatment strategies and goals before conducting exposure can have a strong impact on adherence and outcome. Future studies should examine whether there are specific components of therapeutic alliance that predict patient adherence and how to bolster them to maximize EX/RP outcome.

Second, readiness for treatment (measured by the Readiness Ruler) also predicted treatment outcome through patient adherence (n = 28) or treatment readiness, and test whether this leads to improved therapy. Deliver these interventions to those who show poor alliance or treatment readiness, and test whether this leads to improved patient adherence and thereby outcome, as our findings suggest.

If these findings are replicated, future research should develop interventions to enhance therapeutic alliance and treatment readiness, and test whether this leads to improved patient adherence and thereby outcome, as our findings suggest.

Acknowledgements
This study was funded by a grant from the National Institutes of Mental Health (R34 MH071570) and by a 2005 NARSAD Young Investigator Award to Dr. Simpson. We thank Stephen and Constance Lieber for supporting the first author as a NARSAD Lieber Investigator. We thank members of the Anxiety Disorders Clinic for help with the conduct of this trial. We also thank Shawn Cahill for helping with EX/RP supervision and Naihua Duan for consulting on the statistical plan.

Disclosure Statement
None of the authors have financial interests to disclose with three exceptions. Dr. Simpson has received research support from NIMH, NARSAD, the OC Foundation, Janssen Pharmaceuticals,

### Table 1. Individual predictors of patient adherence (between-session PEAS) and their indirect effects on treatment outcome through patient adherence (n = 28)

| Predictors | Mean (SD) or n (%) | Estimated coefficient (beta)<sup>a</sup> | 95% CI | p value | Indirect effects | 95% CI | p value |
|------------|--------------------|----------------------------------------|-------|--------|-----------------|-------|--------|
| Therapeutic alliance (WAI-SR) | 62.14 (8.14) | 0.72 | 0.44, 0.99 | <0.001 | –0.30 | –0.48, –0.12 | <0.01 |
| Treatment expectancy (EQ) | –0.04 (2.67) | 0.65 | 0.35, 0.95 | <0.001 | –0.08 | –0.08, 0.05 | 0.23 |
| Treatment readiness (RR) | 8.09 (1.40) | 0.53 | 0.19, 0.86 | 0.003 | –0.21 | –0.36, –0.07 | <0.01 |
| Hoarding subtype | 4 (14%) | –0.44 | –0.78, –0.08 | 0.019 | 0.15 | 0.02, 0.28 | 0.03 |
| Work impairment (SDS) | 5.89 (2.75) | –0.38 | –0.74, –0.02 | 0.040 | 0.01 | –0.08, 0.10 | 0.89 |
| Readiness for change (URICA) | 10.78 (1.62) | 0.39 | 0.01, 0.77 | 0.043 | –0.01 | –0.10, 0.08 | 0.89 |
| Depression severity (HAM-D) | 8.36 (5.34) | –0.28 | –0.66, 0.10 | 0.136 | – | – | – |
| Baseline OCD severity (Y-BOCS) | 27.75 (4.06) | –0.25 | –0.67, 0.15 | 0.202 | – | – | – |
| Number of current Axis-I disorders | 1.73 (0.87) | –0.21 | –0.60, 0.18 | 0.273 | – | – | – |
| Insight (BABS) | 5.82 (4.85) | –0.19 | –0.57, 0.20 | 0.334 | – | – | – |
| Total number of SRI trials | 1.32 (1.74) | –0.28 | –0.66, 0.10 | 0.140 | – | – | – |
| Quality of life (Q-LES-Q) | 49.86 (16.90) | 0.27 | –0.12, 0.66 | 0.172 | – | – | – |
| Employed or student | 17 (61%) | 0.14 | –0.26, 0.54 | 0.489 | – | – | – |
| Female gender | 13 (46%) | –0.67 | –0.47, 0.33 | 0.733 | – | – | – |

<sup>a</sup> Simple correlation of each predictor with patient adherence.
<sup>b</sup> Standardized indirect effect estimates from mediation analyses controlling for baseline Y-BOCS. Estimates represent the independent effect of each predictor on outcome mediated by patient adherence.

BABS = Brown Assessment of Beliefs Scale (measured at baseline); CI = confidence interval; EQ = Expectancy Questionnaire (measured after visit 3); HAM-D = Hamilton Depression Rating Scale (measured at baseline); SRI = serotonin reuptake inhibitor; URICA = University of Rhode Island Change Assessment (measured after visit 3); WAI-SR = Working Alliance Inventory – Self Report (measured after visit 3); Y-BOCS = Yale-Brown Obsessive-Compulsive Scale (measured at baseline). Variables assessed after visit 3 were measured before EX/RP started.
Neuropharm Ltd, and Transcept Pharmaceuticals, Inc. She has consulted for Pfizer and Jazz Pharmaceuticals. She received royalties from the sale of Anxiety Disorders: Theory, Research, and Clinical Perspectives. Dr. Foa has received research support from Pfizer, Solvay, Eli Lilly, SmithKline Beecham, GlaxoSmithKline, Cephalon, Bristol Myers Squibb, Forest, Ciba Geigy, Kali-Duphar, and the American Psychiatric Association. She has been a speaker for Pfizer, GlaxoSmithKline, Forest Pharmaceuticals, the American Psychiatric Association, and Jazz Pharmaceuticals. She has been a consultant for Actelion Pharmaceuticals. She receives royalties from the sale of Stop Obsessing and Mastery of Your Obsessive-Compulsive Disorder. Dr. Franklin has NIMH research grant funding and received past grant funding from the Tourette Syndrome Association.

References

1. Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR: Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry 2006;67:269–276.
2. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X: Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005;162:151–161.
3. Simpson HB, Zuckoff AM, Maher MJ, Page JR, Franklin ME, Foa EB, Schmidt AB, Wang Y: Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorder. Behav Res Ther 2010;48:941–948.
4. Simpson HB, Maher MJ, Wang Y, Bao Y, Foa EB, Franklin M: Patient adherence predicts outcome from cognitive behavioral therapy in obsessive-compulsive disorder. J Consult Clin Psychol 2011;79:247–252.
5. De Araujo LA, Ito LM, Marks IM: Early compliance and other factors predicting outcome of exposure for obsessive-compulsive disorder. Br J Psychiatry 1996;169:747–752.
6. Kozak MJ, Foa EB: Mastery of Obsessive-Compulsive Disorder: A Cognitive-Behavioral Approach. San Antonio, The Psychological Corporation, 1997.
7. Simpson HB, Maher M, Page JR, Gibbons CJ, Franklin ME, Foa EB: Development of a patient adherence scale for exposure and response prevention therapy. Behav Ther 2010;41:30–37.
8. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive-Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006–1011.
9. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-Brown Obsessive-Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989;46:1012–1016.
10. Devilly GJ, Borkovec TD: Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry 2000;31:73–86.
11. Dozois DJA, Westra HA, Collins KA, Fung TS, Garry JKF: Stages of change in anxiety: Psychometric properties of the University of Rhode Island Change Assessment (URICA) scale. Behav Res Ther 2004;42:711–729.
12. Halperin DM, Weitzman ML, Otto MW: Therapeutic alliance and common factors in treatment; in Otto MW, Hofmann SG (eds): Avoiding Treatment Failures in the Anxiety Disorders. New York, Springer, 2010.
13. McConnaughey EA, DiClemente CC, Prochaska JO, Velicer WF: Stages of change in psychotherapy: A follow-up report. Psychotherapy 1989;26:368–375.
14. Maher MJ, Huppert JD, Chen H, Duan N, Foa EB, Liebowitz MR, Simpson HB: Moderators and predictors of response to cognitive-behavioral therapy augmentation of pharmacotherapy in obsessive-compulsive disorder. Psychol Med 2010;40:2013–2023.
15. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
16. Eisen JL, Phillips KA, Baer L, Beer DA, Atala KD, Rasmussen SA: The brown assessment of beliefs scale: Reliability and validity. Am J Psychiatry 1998;155:102–108.
17. Endicott J, Nee J, Harrison W, Blumenthal R: Quality of life enjoyment and satisfaction questionnaire: A new measure. Psychopharmacol Bull 1993;29:321–326.
18. First MB, Spitzer RL, Gibbon M, Williams JB: Structured clinical interview for DSM-IV Axis I disorders – patient edition. New York, Biometrics Research Department, New York State Psychiatric Institute, 1996.
19. Sheehan DV: The anxiety disease. New York, Scribner’s, 1983.
20. MacKinnon DP, Lockwood CM, Williams JB: Confidence limits for the indirect effect: Distribution of the product and resampling methods. Multivariate Behav Res 2004;39:99–128.
21. Frost RO, Tolin DF, Maltby N: Insight-related challenges in the treatment of hoarding. Cogn Behav Pract 2010;17:404–413.
22. Stikets G, Frost RO: Compulsive Hoarding and Acquiring: Workbook. New York, Oxford University Press, 2007.

Helen Blair Simpson, MD, PhD
New York State Psychiatric Institute
1051 Riverside Drive, Unit 69
New York, NY 10032 (USA)
Tel. +1 212 543 6532, E-Mail simpson@nyspi.cpmc.columbia.edu